Sai Sreyas Pharmaceutical is an API manufacturer based in India. It holds 11 active US drug master files across a filed portfolio of 6 molecules. Customs aggregates show $205K of exports covering 22 molecules to 7 destinations in 2025.
| Molecule | Regulators | Docs |
|---|---|---|
| Rivaroxaban | US FDA | 3 |
| Empagliflozin | US FDA | 2 |
| Olanzapine | US FDA | 2 |
| Resmetirom | US FDA | 2 |
| Alectinib | US FDA | 1 |
| Sitagliptin | US FDA | 1 |
Also appears on these molecule pages
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | Not reported | $205K | 7 |
| 2024 | Not reported | $35K | 4 |
| 2023 | Not reported | $227 | 1 |
| 2022 | Not reported | $712 | 1 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Sai Sreyas Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free